Inhaled Murepavadin
Cystic Fibrosis (Pseudomonas aeruginosa infection)
Phase 1Active
Key Facts
About Spexis
Spexis AG is a publicly traded biopharma focused on discovering and developing novel macrocyclic therapeutics for rare diseases and cancer. Its strategy is built upon two proprietary technology platforms: a Macrocycle Platform for undruggable targets and an OMPTA Platform for antibiotic-resistant Gram-negative infections. The company's most advanced program, ColiFin®, is an approved inhaled therapy for cystic fibrosis, positioning Spexis with a late-stage asset while advancing earlier clinical and pre-clinical candidates. Spexis is actively seeking development and commercialization partners to maximize the value of its pipeline and platforms.
View full company profile